Bailard’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Bailard’s Portfolio YARW Stock Details YARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-155	Closed	-$91K	–	803
2022 Q1	$91K	Buy	+155	New	+$92.1K	﹤0.01%	698

Other funds holding YARW

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Bailard's YARW Position: Q2 2022 in Review

Bailard sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q2 2022, closing a stake of 155 shares — an estimated $91K sold.

Bailard first reported a position in YARW in Q1 2022 and held it in 1 quarter. The position peaked at $91K in Q1 2022. 37 funds tracked by Wall St. Rank hold YARW as of Q2 2022.

Bailard reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bailard sold 155 Yarrow Bioscience, Inc. Common Stock shares in Q2 2022, an estimated $91K.
Bailard first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
Bailard's Yarrow Bioscience, Inc. Common Stock position peaked at $91K in Q1 2022.
37 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.